Pharmacotherapy in stroke rehabilitation

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 8, 2009, Pages 1249-1259

  Członkowska, Anna ^a,b   Leśniak, Marcin ^b  

^a INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Neurorehabilitation; Pharmacotherapy; Recovery; Stroke

Indexed keywords

AMANTADINE; AMITRIPTYLINE; AMPHETAMINE; BACLOFEN; BENZODIAZEPINE DERIVATIVE; BROMOCRIPTINE; CHOLINERGIC RECEPTOR STIMULATING AGENT; CITALOPRAM; CLONIDINE; DEXAMPHETAMINE; DONEPEZIL; ERYTHROPOIETIN; FIBROBLAST GROWTH FACTOR 2; FLUOXETINE; GRANULOCYTE COLONY STIMULATING FACTOR; HALOPERIDOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEVODOPA; MAPROTILINE; METHYLPHENIDATE; MOCLOBEMIDE; NORTRIPTYLINE; PIRACETAM; PLACEBO; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; THREO 3,4 DIHYDROXYPHENYLSERINE; TIZANIDINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ADDICTION; AGITATION; ANOREXIA; APHASIA; APPETITE; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; BIPOLAR DISORDER; BLOOD PRESSURE; BRAIN INJURY; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONFUSION; CONSCIOUSNESS DISORDER; CONSTIPATION; DEPRESSION; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; EDEMA; ELECTROENCEPHALOGRAM; HALLUCINATION; HUMAN; HYPERTENSION; HYPOTENSION; INSOMNIA; INVOLUNTARY MOVEMENT; MOTOR DYSFUNCTION; MUSCLE WEAKNESS; NEGLECT; NERVE CELL PLASTICITY; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PHYSIOTHERAPY; PORPHYRIA; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; SPASTICITY; SPEECH THERAPY; STEM CELL TRANSPLANTATION; STROKE; TACHYCARDIA; TIC; TRANSIENT ISCHEMIC ATTACK; TRAUMATIC BRAIN INJURY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VERTIGO;

HUMANS; NOOTROPIC AGENTS; STROKE; TREATMENT OUTCOME;

EID: 67649675093     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560902941972     Document Type: Review

References (95)

1. Chen J, Chopp M. Neurorestorative treatment of stroke: cell and pharmacological approaches. NeuroRx 2006;3(4):466-473 (Pubitemid 44443015)
2. Hummel FC, Cohen LG. Drivers of brain plasticity. Curr Opin Neurol 2005;18(6):667-674 (Pubitemid 41669140)
3. Wagner T, Valero-Cabre A, Pascual-Leone A. Noninvasive human brain stimulation. Annu Rev Biomed Eng 2007;9:527-565 (Pubitemid 350246667)
4. Cramer SC. Repairing the human brain after stroke. II: restorative therapies. Ann Neurol 2008;63(5):549-560
5. Seil F. Recovery and repair issues after stroke from the scientific perspective. Curr Opin Neurol 1997;10:49-51 (Pubitemid 27136242)
6. Carmichael ST. Cellular and molecular mechanisms of neural repair after stroke: making waves. Ann Neurol 2006;59(5):735-742 (Pubitemid 43673150)
7. Rossini PM, Pauri F. Neuromagnetic integrated methods tracking human brain mechanisms of sensorimotor areas 'plastic' reorganisation. Brain Res Brain Res Rev 2000;33(2-3):131-154
8. Rijntjes M, Weiller C. Recovery of motor and language abilities after stroke: the contribution of functional imaging. Prog Neurobiol 2002;66(2):109-122 (Pubitemid 34251169)
9. Butefisch CM, Kleiser R, Seitz RJ. Post-lesional cerebral reorganisation: evidence from functional neuroimaging and transcranial magnetic stimulation. J Physiol Paris 2006;99(4-6):437-454 (Pubitemid 43850796)
10. Taupin P. Adult neurogenesis pharmacology in neurological diseases and disorders. Expert Rev Neurother 2008;8(2):311-320 (Pubitemid 351281116)
11. Zorowitz RD. Road to recovery: drugs used in stroke rehabilitation. Expert Rev Neurother 2004;4(2):219-231 (Pubitemid 38315942)
12. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 1999;30(12):2752-2758
13. O'Collins VE, Macleod MR, Donnan GA, et al. 1,026 experimental treatments in acute stroke. Ann Neurol 2006;59(3):467-477
14. Członkowski A, Mirowska-Guzel D, Członkowska A. Therapy of stroke - from experimental studies to clinical trials. Pharmacol Rep 2007;59(Suppl 1):123-128
15. Muresanu DF. Neuroprotection and neuroplasticity - a holistic approach and future perspectives. J Neurol Sci 2007;257(1-2):38-43 (Pubitemid 46856502)
16. Donnan GA. The 2007 Feinberg lecture: a new road map for neuroprotection. Stroke 2008;39(1):242
17. Cramer SC. Repairing the human brain after stroke: I. mechanisms of spontaneous recovery. Ann Neurol 2008;63(3):272-287
18. Rijntjes M. Mechanisms of recovery in stroke patients with hemiparesis or aphasia: new insights, old questions and the meaning of therapies. Curr Opin Neurol 2006;19(1):76-83 (Pubitemid 43172709)
19. Bütefisch CM, Netz J, Wessling M, et al. Remote changes in cortical excitability after stroke. Brain 2003;126:470-481 (Pubitemid 36172751)
20. Baron JC. Stroke research in the modern era: images versus dogmas. Cerebrovasc Dis 2005;20(3):154-163 (Pubitemid 41254176)
21. Seitz RJ, Azari NP, Knorr U, et al. The role of diaschisis in stroke recovery. Stroke 1999;30(9):1844-1850 (Pubitemid 29411825)
22. Kreisel SH, Bazner H, Hennerici MG. Pathophysiology of stroke rehabilitation: temporal aspects of neuro-functional recovery. Cerebrovasc Dis 2006;21(1-2):6-17 (Pubitemid 43110304)
23. Goldstein LB. Influence of common drugs and related factors on stroke outcome. Curr Opin Neurol 1997;10:52-57 (Pubitemid 27136243)
24. Goldstein LB, Davis JN. Clonidine impairs recovery of beam-walking after a sensorimotor cortex lesion in the rat. Brain Res 1990;508(2):305-309 (Pubitemid 20063467)
25. Goldstein LB. Common drugs may influence motor recovery after stroke. the Sygen in Acute Stroke Study investigators. Neurology 1995;45(5):865-871
26. Stroemer RP, Kent TA, Hulsebosch CE. Enhanced neocortical neural sprouting, synaptogenesis, and behavioral recovery with D-amphetamine therapy after neocortical infarction in rats. Stroke 1998;29(11):2381-93; discussion 2393-2395 (Pubitemid 28511963)
27. Martinsson L, Hardemark HG, Eksborg S. Amphetamines for improving recovery after stroke (review). United States: John Wiley 'Sons, Ltd; 2008 A comprehensive systematic review of 10 randomised trials.
28. Mintz M, Tomer R. Exposure to amphetamine after substantia nigra lesion interferes with the process of behavioral recovery. Pharmacol Biochem Behav 1986;25(6):1307-1311 (Pubitemid 17212816)
29. Martinsson L, Eksborg S. Drugs for stroke recovery: the example of amphetamines. Drugs Aging 2004;21(2):67-79 (Pubitemid 38293787)
30. Sonde L, Lokk J. Effects of amphetamine and/or L-dopa and physiotherapy after stroke: a blinded randomized study. Acta Neurol Scand 2007;115(1):55-59 (Pubitemid 44915499)
31. Martinsson L, Hardemark HG, Eksborg S. Should amphetamines be given to improve recovery after stroke? Stroke 2007;38:2400-2401
32. Gladstone DJ, Danells CJ, Armesto A, et al. Physiotherapy coupled with dextroamphetamine for rehabilitation after hemiparetic stroke: a randomized, double-blind, placebo-controlled trial. Stroke 2006;37(1):179-185 (Pubitemid 43732068)
33. Walker-Batson D, Curtis S, Natarajan R, et al. A double-blind, placebo-controlled study of the use of amphetamine in the treatment of aphasia. Stroke 2001;32(9):2093-2098 (Pubitemid 32868104)
34. Weikop P, Yoshitake T, Kehr J. Differential effects of adjunctive methylphenidate and citalopram on extracellular levels of serotonin, noradrenaline and dopamine in the rat brain. Eur Neuropsychopharmacol 2007;17(10):658-671 (Pubitemid 47277501)
35. Grade C, Redford B, Chrostowski J, et al. Methylphenidate in early poststroke recovery: a double-blind, placebo-controlled study. Arch Phys Med Rehabil 1998;79(9):1047-1050 (Pubitemid 28419310)
36. Poewe W. Non-motor symptoms in Parkinson's disease. Eur J Neurol 2008;15(Suppl 1):14-20
37. Nishino K, Sasaki T, Takahashi K, et al. The norepinephrine precursor L-threo-3,4-dihydroxyphenylserine facilitates motor recovery in chronic stroke patients. J Clin Neurosci 2001;8(6):547-550 (Pubitemid 33089505)
38. Yan HQ, Kline AE, Ma X, etal. Traumatic brain injury reduces dopamine transporter protein expression in the rat frontal cortex. Neuroreport 2002;13(15):1899-1901
39. Nutt JG. Pharmacokinetics and pharmacodynamics of levodopa. Mov Disord 2008;23(Suppl 3):S580-4
40. Knecht S, Breitenstein C, Bushuven S, et al. Levodopa: faster and better word learning in normal humans. Ann Neurol 2004;56(1):20-6 41. Scheidtmann K, Fries W, Muller F, Koenig E. Effect of levodopa in combination with physiotherapy on functional motor recovery after stroke: a prospective, randomised, double-blind study. Lancet 2001;358(9284):787-790 A randomised controlled trial that demonstrates beneficial effects of levodopa in stroke rehabilitation. (Pubitemid 38857356)
41. Restemeyer C, Weiller C, Liepert J. No effect of a levodopa single dose on motor performance and motor excitability in chronic stroke. A double-blind placebo-controlled cross-over pilot study. Restor Neurol Neurosci 2007;25(2):143-150
42. Floel A, Hummel F, Breitenstein C, et al. Dopaminergic effects on encoding of a motor memory in chronic stroke. Neurology 2005;65(3):472-474 (Pubitemid 41099818)
43. Mukand JA, Guilmette TJ, Allen DG, et al. Dopaminergic therapy with carbidopa L-dopa for left neglect after stroke: a case series. Arch Phys Med Rehabil 2001;82(9):1279-1282 (Pubitemid 32845895)
44. Seniów J, Litwin M, Litwin T, etal. New approach to the rehabilitation of poststroke focal cognitive syndrome: effect of levodopa combined with speech and language therapy on functional recovery from aphasia. J Neurol Sci 2008 In press
45. Ashtary F, Janghorbani M, Chitsaz A, et al. A randomized, double-blind trial of bromocriptine efficacy in nonfluent aphasia after stroke. Neurology 2006;66(6):914-916
46. Gupta SR, Mlcoch AG, Scolaro C, Moritz T. Bromocriptine treatment of nonfluent aphasia. Neurology 1995;45(12):2170-2173 (Pubitemid 27100242)
47. Bragoni M, Altieri M, Di Piero V, et al. Bromocriptine and speech therapy in non-fluent chronic aphasia after stroke. Neurol Sci 2000;21(1):19-22 (Pubitemid 30430854)
48. Sabe L, Salvarezza F, Garcia Cuerva A, et al. A randomized, double-blind, placebo-controlled study of bromocriptine in nonfluent aphasia. Neurology 1995;45(12):2272-2274 (Pubitemid 27100261)
49. Mandel S, Grunblatt E, Riederer P, et al. Neuroprotective strategies in Parkinson's disease: an update on progress. CNS Drugs 2003;17(10):729-762 (Pubitemid 37000010)
50. Gerdelat-Mas A, Loubinoux I, Tombari D, et al. Chronic administration of selective serotonin reuptake inhibitor (SSRI) paroxetine modulates human motor cortex excitability in healthy subjects. Neuroimage 2005;27(2):314-322 (Pubitemid 41074834)
51. Kline AE, Yu J, Massucci JL, et al. Protective effects of the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin against traumatic brain injury-induced cognitive deficits and neuropathology in adult male rats. Neurosci Lett 2002;333(3):179-182 (Pubitemid 35335772)
52. Wiart L, Petit H, Joseph PA, et al. Fluoxetine in early poststroke depression: a double-blind placebo-controlled study. Stroke 2000;31(8):1829-1832 (Pubitemid 30620458)
53. Arce E, Simmons AN, Lovero KL, et al. Escitalopram effects on insula and amygdala BOLD activation during emotional processing. Psychopharmacology (Berl) 2008;196(4):661-672
54. Paranthaman R, Baldwin RC. Treatment of psychiatric syndromes due to cerebrovascular disease. Int Rev Psychiatry 2006;18(5):453-470 (Pubitemid 44691445)
55. Fruehwald S, Gatterbauer E, Rehak P, Baumhackl U. Early fluoxetine treatment of post-stroke depression-a three-month double-blind placebo-controlled study with an open-label long-term follow up. J Neurol 2003;250(3):347-351 (Pubitemid 36399276)
56. Dam M, Tonin P, De Boni A, etal. Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy. Stroke 1996;27(7):1211-1214
57. Pariente J, Loubinoux I, Carel C, et al. Fluoxetine modulates motor performance and cerebral activation of patients recovering from stroke. Ann Neurol 2001;50(6):718-729 (Pubitemid 33116131)
58. Robinson RG, Schultz SK, Castillo C, et al. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. Am J Psychiatry 2000;157(3):351-359 (Pubitemid 30145919)
59. Zittel S, Weiller C, Liepert J. Reboxetine improves motor function in chronic stroke. A pilot study. J Neurol 2007;254(2):197-201 (Pubitemid 46356052)
60. Zittel S, Weiller C, Liepert J. Citalopram improves dexterity in chronic stroke patients. Neurorehabil Neural Repair 2008;22(3):311-314 (Pubitemid 351561669)
61. Laska AC, von Arbin M, Kahan T, et al. Long-term antidepressant treatment with moclobemide for aphasia in acute stroke patients: a randomised, double-blind, placebo-controlled study. Cerebrovasc Dis 2005;19(2):125-132 (Pubitemid 40278672)
62. Berthier ML, Hinojosa J, Martin Mdel C, Fernandez I. Open-label study of donepezil in chronic poststroke aphasia. Neurology 2003;60(7):1218-1219 (Pubitemid 36418800)
63. Berthier ML, Pujol J, Gironell A, et al. Beneficial effect of donepezil on sensorimotor function after stroke. Am J Phys Med Rehabil 2003;82(9):725-729 (Pubitemid 37022523)
64. Bakheit AM. Drug treatment of poststroke aphasia. Expert Rev Neurother 2004;4(2):211-217 (Pubitemid 38315941)
65. Kessler J, Thiel A, Karbe H, Heiss WD. Piracetam improves activated blood flow and facilitates rehabilitation of poststroke aphasic patients. Stroke 2000;31(9):2112-2116 (Pubitemid 30702780)
66. Enderby P, Broeckx J, Hospers W, et al. Effect of piracetam on recovery and rehabilitation after stroke: a double-blind, placebo-controlled study. Clin Neuropharmacol 1994;17(4):320-331 (Pubitemid 24239382)
67. Huber W, Willmes K, Poeck K, et al. Piracetam as an adjuvant to language therapy for aphasia: a randomized double-blind placebo-controlled pilot study. Arch Phys Med Rehabil 1997;78(3):245-250 (Pubitemid 27120256)
68. De Deyn PP, Reuck JD, Deberdt W, et al. Treatment of acute ischemic stroke with piracetam. members of the piracetam in acute stroke study (PASS) group. Stroke 1997;28(12):2347-2352
69. Huber W. The role of piracetam in the treatment of acute and chronic aphasia. Pharmacopsychiatry 1999;32(Suppl 1):38-43
70. Ricci S, Celani MG, Cantisani AT, Righetti E. Piracetam for acute ischaemic stroke. Cochrane Database Syst Rev 2006;(2):CD000419 (Pubitemid 46841361)
71. Greener J, Enderby P, Whurr R. Pharmacological treatment for aphasia following stroke. Cochrane Database Syst Rev 2001;(4):CD000424
72. Duncan PW, Zorowitz R, Bates B, et al. Management of adult stroke rehabilitation care: a clinical practice guideline. Stroke 2005;36(9):e100-43
73. Romano JG, Sacco RL. Progress in secondary stroke prevention. Ann Neurol 2008;63:418-427 (Pubitemid 351637501)
74. Chen J, Zhang ZG, Li Y, et al. Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol 2003;53(6):743-751 (Pubitemid 36622511)
75. Blanco M, Nombela F, Castellanos M, et al. Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology 2007;69(9):904-910 (Pubitemid 47329591)
76. Shyu WC, Lin SZ, Yang HI, et al. Functional recovery of stroke rats induced by granulocyte colony-stimulating factor-stimulated stem cells. Circulation 2004;110(13):1847-1854 (Pubitemid 39299228)
77. Zhao LR, Singhal S, Duan WM, et al. Brain repair by hematopoietic growth factors in a rat model of stroke. Stroke 2007;38(9):2584-2591 (Pubitemid 47329641)
78. Sehara Y, Hayashi T, Deguchi K, et al. Potentiation of neurogenesis and angiogenesis by G-CSF after focal cerebral ischemia in rats. Brain Res 2007;1151:142-149 (Pubitemid 46709859)
79. Ehrenreich H, Hasselblatt M, Dembowski C, et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002;8(8):495-505 (Pubitemid 36337492)
80. Kleim JA, Chan S, Pringle E, etal. BDNF val66met polymorphism is associated with modified experience-dependent plasticity in human motor cortex. Nat Neurosci 2006;9(6):735-737
81. Lindvall O, Kokaia Z. Recovery and rehabilitation in stroke. Stem cells. Stroke 2004;35(Suppl 1):2691-2694
82. Cairns K, Finklestein S. Growth factors and stem cells as treatments for stroke recovery. Phys Med Revabil Clin N Am 2003;14:135-142 (Pubitemid 36259036)
83. Pastori C, Librizzi L, Breschi GL, et al. Arterially perfused neurosphere-derived cells distribute outside the ischemic core in a model of transient focal ischemia and reperfusion in vitro. PLoS ONE 2008;3(7):e2754
84. Sprigg N, Bath P. Pharmacological enhancement of recovery from stroke. Curr Med Lit Stroke Rev 2005;8:33-39
85. Wilson MS, Gibson CJ, Hamm RJ. Haloperidol, but not olanzapine, impairs cognitive performance after traumatic brain injury in rats. Am J Phys Med Rehabil 2003;82(11):871-879 (Pubitemid 37310050)
86. Sims JS, Jones TA, Fulton RL. Benzodiazepines effects on recovery of function linked to transneuronal morphological events. Soc Neurosci Abstr 1990;16:342
87. Lazar RM, Fitzsimmons BF, Marshall RS, et al. Midazolam challenge reinduces neurological deficits after transient ischemic attack. Stroke 2003;34(3):794-796 (Pubitemid 36307413)
88. Gelber DA, Good DC, Dromerick A, et al. Open-label dose-titration safety and efficacy study of tizanidine hydrochloride in the treatment of spasticity associated with chronic stroke. Stroke 2001;32(8):1841-1846 (Pubitemid 32772217)
89. Bates B, Choi JY, Duncan PW, etal. US Department of Defense; Department of Veterans Affairs. Veterans Affairs/Department of Defense Clinical Practice Guideline for the Management of Adult Stroke Rehabilitation Care: executive summary. Stroke 2005;36(9):2049-2056
90. Goldstein LB. Potential effects of common drugs on stroke recovery. Arch Neurol 1998;55(4):454-456 (Pubitemid 28182689)
91. Hasselt PV. Effect of butyrophenones on motor function in rats after recovery from brain damage. Neuropharmacology 1973;12(3):245-247
92. Feeney DM, Westerberg VS. Norepinephrine and brain damage: alpha noradrenergic pharmacology alters functional recovery after cortical trauma. Can J Psychol 1990;44(2):233-252
93. Rosser N, Floel A. Pharmacological enhancement of motor recovery in subacute and chronic stroke. NeuroRehabilitation 2008;23(1):95-103 (Pubitemid 352038566)
94. Leśniak M, Bak T, Czepiel W, et al. The frequency and prognostic value of cognitive disorders in stroke patients. Dement Geriatr Cogn Disord 2008;26:356-363
95. Liepert J. Pharmacotherapy in restorative neurology. Curr Opin Neurol 2008;21:639-643